SLN

Silence Therapeutics (SLN)

Silence Therapeutics PLC

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:SLN

1 2 3 4 5 6 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/20	20 : 30	Business Wire	Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)	NASDAQ:SLN	Silence Therapeutics PLC
2024/05/30	21 : 30	Business Wire	Silence Therapeutics to Present at Jefferies Global Healthcare Conference	NASDAQ:SLN	Silence Therapeutics PLC
2024/05/18	06 : 04	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:SLN	Silence Therapeutics PLC
2024/05/17	03 : 21	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:SLN	Silence Therapeutics PLC
2024/05/16	21 : 30	Business Wire	Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress	NASDAQ:SLN	Silence Therapeutics PLC
2024/05/15	05 : 27	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:SLN	Silence Therapeutics PLC
2024/05/09	06 : 14	Edgar (US Regulatory)	Form DEL AM - Delaying amendment	NASDAQ:SLN	Silence Therapeutics PLC
2024/04/30	21 : 30	Business Wire	Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference	NASDAQ:SLN	Silence Therapeutics PLC
2024/04/29	21 : 30	Business Wire	Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors	NASDAQ:SLN	Silence Therapeutics PLC
2024/04/09	00 : 48	Business Wire	Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)	NASDAQ:SLN	Silence Therapeutics PLC
2024/03/13	20 : 05	Business Wire	Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights	NASDAQ:SLN	Silence Therapeutics PLC
2024/03/13	20 : 03	IH Market News	Mixed Futures Amidst Quiet Economic Schedule; Oil Prices Climb	NASDAQ:SLN	Silence Therapeutics PLC
2024/03/13	20 : 00	Business Wire	Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)	NASDAQ:SLN	Silence Therapeutics PLC
2024/02/28	22 : 00	Business Wire	Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024	NASDAQ:SLN	Silence Therapeutics PLC
2024/02/23	22 : 12	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:SLN	Silence Therapeutics PLC
2024/02/23	22 : 00	Business Wire	Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial	NASDAQ:SLN	Silence Therapeutics PLC
2024/02/14	23 : 54	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:SLN	Silence Therapeutics PLC
2024/02/14	22 : 55	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:SLN	Silence Therapeutics PLC
2024/02/05	22 : 00	Business Wire	Silence Therapeutics Announces Oversubscribed $120 Million Private Placement	NASDAQ:SLN	Silence Therapeutics PLC
2024/01/31	21 : 00	Business Wire	Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	NASDAQ:SLN	Silence Therapeutics PLC
2023/12/01	21 : 00	Business Wire	Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments	NASDAQ:SLN	Silence Therapeutics PLC
2023/11/14	21 : 00	Business Wire	Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results	NASDAQ:SLN	Silence Therapeutics PLC
2023/11/08	21 : 00	Business Wire	Silence Therapeutics to Present at Jefferies London Healthcare Conference	NASDAQ:SLN	Silence Therapeutics PLC
2023/11/01	20 : 00	Business Wire	Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease	NASDAQ:SLN	Silence Therapeutics PLC
2023/09/26	20 : 00	Business Wire	Silence Therapeutics to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference	NASDAQ:SLN	Silence Therapeutics PLC
2023/09/06	20 : 00	Business Wire	Silence Therapeutics to Participate in September Investor Conferences	NASDAQ:SLN	Silence Therapeutics PLC
2023/08/30	05 : 01	Edgar (US Regulatory)	Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]	NASDAQ:SLN	Silence Therapeutics PLC
2023/08/16	20 : 00	Business Wire	Silence Therapeutics Reports Second Quarter 2023 Results	NASDAQ:SLN	Silence Therapeutics PLC
2023/08/02	05 : 31	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:SLN	Silence Therapeutics PLC
2023/07/11	20 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:SLN	Silence Therapeutics PLC